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Background: Noopept (N-phenyl-acetyl-L-prolylglycine ethyl ester) was constructed as a dipeptide analog of the
standard cognition enhancer, piracetam. Our previous experiments have demonstrated the cognition restoring effect
of noopept in several animal models of Alzheimer disease (AD). Noopept was also shown to prevent ionic disbalance,
excitotoxicity, free radicals and pro-inflammatory cytokines accumulation, and neurotrophine deficit typical for different
kinds of brain damages, including AD. In this study, we investigated the neuroprotective action of noopept on cellular
model of AD, Aβ25–35-induced toxicity in PC12 cells and revealed the underlying mechanisms.
Results: The neuroprotective effect of noopept (added to the medium at 10 μM concentration, 72 hours before Аβ25–35)
was studied on Аβ25–35-induced injury (5 μM for 24 h) in PC12 cells. The ability of drug to protect the impairments of cell
viability, calcium homeostasis, ROS level, mitochondrial function, tau phosphorylation and neurite outgrowth caused by
Аβ25–35 were evaluated.
Following the exposure of PC12 cells to Аβ25–35 an increase of the level of ROS, intracellular calcium, and tau
phosphorylation at Ser396 were observed; these changes were accompanied by a decrease in cell viability and an
increase of apoptosis. Noopept treatment before the amyloid-beta exposure improved PC12 cells viability, reduced the
number of early and late apoptotic cells, the levels of intracellular reactive oxygen species and calcium and enhanced
the mitochondrial membrane potential. In addition, pretreatment of PC12 cell with noopept significantly attenuated tau
hyperphosphorylation at Ser396 and ameliorated the alterations of neurite outgrowth evoked by Аβ25–35.
Conclusions: Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell
against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing
the mitochondrial apoptotic pathway. Moreover, neuroprotective properties of noopept likely include its ability to
decrease tau phosphorylation and to restore the altered morphology of PC12 cells. Therefore, this nootropic dipeptide
is able to positively affect not only common pathogenic pathways but also disease-specific mechanisms underlying
Aβ-related pathology.
Keywords: Alzheimer’s disease, Noopept, Beta-amyloid, Tau phosphorylation, Neurites outgrowth* Correspondence: juvv73@gmail.com
2Institute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect
Oktyabrya, 71, 450054 Ufa, Russia
Full list of author information is available at the end of the article
© 2014 Ostrovskaya et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Figure 1 Chemical structures of piracetam and noopept. The
structural similarity of piracetam (A) to noopept (B). Both molecules
contain pyrrolidine ring, acylated nitrogen in this ring, amide moiety
and the fragment of glycine.
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Alzheimer’s disease (AD) is the most common form of
neurodegenerative disease, accompanied by age-related
dementia, affecting 27 million individuals worldwide [1].
Mechanisms underlying the progression of late-onset
AD consist of a number of interacting events including
excessive accumulation of amyloid, aberrant tau-protein
phosphorylation, oxidative stress, chronic inflammatory
conditions, excitotoxicity, disruption of neurotrophine sig-
naling, impairments in cytoskeleton stability and axonal
transport, synaptic and neuronal loss [2]. Pharmacological
treatment of AD currently involves cholinesterase inhi-
bitors and NMDA receptor antagonists. Unfortunately,
according to most investigators therapeutics of both these
groups provide mainly symptomatic benefits without
counteracting the progression of the disease [3].
Drug research in the last decade has attempted to de-
velop disease-modifying drugs hopefully able to delay the
onset or counteract the progression of AD. Strategies
targeting at Aβ pathology include decreasing of Aβ pro-
duction, preventing aggregation of Aβ into amyloid
plaques, stimulating clearance of Aβ. Neither inhibitors of
β-secretase or γ-secretase, nor stimulators of α-secretase
have demonstrated satisfactory potency combined with
low toxicity. Drugs targeting tau-protein are known to be
divided into several groups: modulators of tau phos-
phorylation, inhibitors of tau-phosphorylating kinases (e.g.
glycogen-synthase-kinase-3β, cyclin-dependent kinase-5,
p70-S6-kinase) and compounds that prevent tau aggre-
gation and misfolding [4].
AD is a complex multifactorial pathology, including
multiple cycles and subcycles of self-amplifying neurode-
generative process [5,6]. Monotherapy targeting single
steps in this complicated cascade may explain disappoint-
ments in trials with agents affecting only one chain of this
“circulus vituosus“. So it would be advantageous to ex-
plore the possibilities of novel multi-target therapy, aimed
to affect different disease-related mechanisms, resulting in
additive or synergic therapeutic responses [7].
Neuropeptides have drawn special attention as potential
multitarget drugs because of their high biological activity
(several orders higher than that of nonpeptide ones), avail-
ability of several recognising sites supposed to be com-
plimentary to various targets, the ability to interact with
different signal molecules, and minimal side effects. How-
ever, their usage as drugs is hindered by the poor blood–
brain barrier penetration and low biological stability [8].
Design of dipeptides is one of the promising approaches
taking into account high biological stability of these short
molecules and presence of specific ATP-dependent trans-
port systems for di/tripeptides in the intestine (PEPT1) and
in the blood–brain barrier (PEPT2) [9]. This provides a
basis for brain availability of dipeptides in case of systemic
route of administration, including peroral one.Original approach to the design of active dipeptides is
being developed for many years at V.V. Zakusov Institute
of Pharmacology. Searching for dipeptides with cognitive
enhancing activity Gudasheva et al. based on the idea to
get the structures conformationally close to piracetam as a
standard cognition enhancer [10]. This drug-based pep-
tide design led us to the series of acyl-prolyl-containing di-
peptides possessing pronounced cognitive enhancing and
neuroprotective activities [11]. Noopept (N-phenyl-acetyl-
L-prolylglycine ethyl ester, GVS-111, Noopept®) (Figure 1)
was chosen from this series because of its pronounced
nootropic activity [12], high bioavailability for brain tissues
in case of peroral administration [13] and specificity of its
mechanism of action [14]. Noopept demonstrated wide
spectrum of cognition improving effects [15] as well as
pronounced neuroprotective activities both in vivo [15]
and in vitro conditions [16]. Compared to piracetam
noopept produces a cognition enhancing effect at much
lower concentrations and demonstrates activity over a
wider range of cognition disturbances and neuronal dam-
ages [17]. Noopept showed effectiveness in several animal
models of AD: olfactory bulbectomy [18], administration
of amyloid into Meinert nucleus [19] and intracerebro-
ventricul administration of diabetogenic toxin streptozoto-
cine [20]. Moreover, the experimental data on cognitive
improving effect of noopept have been confirmed in clinic
(Phase III and postregistration trials) demonstrating bene-
ficial effect on cognitive functions in patients with MCI of
cerebro-vascular or posttraumatic origin [21], and in
particular in patients with amnestic form of MCI car-
rying APOE ε4+ allele [22]. Taken together these findings
prompted us to continue the investigation of noopept on
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investigated the protective effect of noopept against
Аβ25–35-mediated damage of PC12 cells, measuring the
cellular viability, apoptosis, intracellular Ca2+, ROS, mito-
chondrial membrane potential, tau protein phosphorylation
level and neurite outgrowth. Aβ25–35 fragment was used as
a peptide mimicking several of the toxic effects of the full-
length amyloid-β peptide and therefore widely exploiting in
both in vitro and in vivo Alzheimer’s disease models [23].
Methods
Cell cultures and treatments
PC12 cells were cultured routinely at 37°C in DMEM
medium, supplemented with 10% fetal bovine serum
(FBS), 5% horse serum, 2 mM L-glutamine, 50 μg/ml gen-
tamicin. To induce PC12 differentiation, NGF (50 ng/ml;
Sigma-Aldrich Inc., USA) was added to the DMEM con-
taining 1% FBS, followed by a 5-day incubation. Differen-
tiated PC12 (dPC12) cells were pretreated with noopept at
concentration of 10 μM for 72 h, then cells were rinsed
with the medium and exposed to amyloid-β-peptide
(Аβ25–35, 5 μM; Tocris Bioscience, UK) for 24 h. Un-
treated cells were used as control.
Cell viability and apoptosis measurements
Cell viability was determined by conventional MTT assay.
dPC12 cells were plated in 24-well plates with 500 μl
DMEM medium at the density of 1 × 104 cells/well. After
treatment with noopept (10 μM) for 72 h followed by
Аβ25–35 (5 μM) for 24 h, cells were incubated with 200 μl
MTT solution (0.5 mg/ml) at 37°C for additional 4 h.
Thereafter the cells were solubilized with 200 μl dimethyl-
sulfoxide. After mixing for 10 min absorbance was mea-
sured at 540 nm using the microplate spectrophotometer
(EnSpire® Multimode Plate Reader; Perkin Elmer, USA).
Cell viability was expressed as the percentage to cell via-
bility in control. Flow cytometry analysis was used to iden-
tify the apoptotic cells. dPC12 cells (5 × 104) in 6-well
plates were treated as described above. Cells were har-
vested, washed out with cold phosphate-buffered saline
(PBS) and stained with the Annexin V/PI (Annexin
V-FITC Kit, Beckman Coulter Inc., USA) according to the
manufacturer’s instructions. The data were processed
using the FCS Express 4 software (De novo Software,
USA) and the Cytomics FC 500 flow cytometer (Beckman
Coulter, USA).
Measurement of intracellular Ca2+
After incubation with noopept and Аβ25–35 dPC12 cells
(1 × 104 cells/well) were washed in Ca2+-free HBSS, con-
taining 2.5 mM probenecid (Tocris Bioscience, UK).
Then cells were loaded with 4 μM of Ca2+ indicator
Fluo-4 AM and 0.02% pluronic acid (Invitrogen, USA)
and incubated for 20 min at 30°C. Cells were washedout twice in buffer without dye, and incubated for
further 15 min. The fluorescence of samples in 0.1 ml of
buffer in new 96-well plates was monitored by the
microplate spectrophotometer, using 485 nm excitation
filter and 520 nm emission filter.
Measurement of intracellular reactive oxygen species
(ROS)
The generation of ROS was measured by the oxidative
conversion of cell permeable 2,7-dichlorofluorescein dia-
cetate (H2DCFDA; Invitrogen, USA) to fluorescent
dichlorofluorescein. dPC12 cells (5 × 103 cells/well) in
96-well plates were cultured for 72 h in 10% DMEM
medium with noopept at concentrations of 10 μM.
H2DCFDA was then added directly to the growth me-
dium at a final concentration of 5 μM; cells were incu-
bated for 1 h at 37°C. Cells were rinsed twice with PBS,
placed in a fresh medium and treated with Аβ25–35
(5 μM) for 24 h. After this treatment cells were washed
out with PBS. The plates were then read on the micro-
plate spectrophotometer with 485 nm excitation and
535 nm emission wavelengths.
Assessment of mitochondrial function
dPC12 cells were plated at a density of 5 × 103 cells/well
in 96-well plates. After treatment with noopept (10 μM)
for 72 h and Аβ25–35 (5 μM) for 24 h changes in the mito-
chondrial membrane potential (MMP) were determined
by incubating with 10 μM of JC-1 reagent (Invitrogen,
USA) for 20 min at 37°C in the darkness. Then the cells
were washed with PBS three times, and the fluorescent in-
tensity was determined by microplate reader.
Western blotting
dPC12 cells (5 × 104 cells/per well) were treated as de-
scribed above and after incubation the cells were har-
vested and suspended in lysis buffer (10 mM Tris, 1 mM
EDTA, 1% SDS, pH 7.5). Protein concentrations were
determined by the Bradford assay and equivalent amounts
(10–15 μg) of total cellular proteins were separated
by electrophoresis on a 12% SDS - polyacrylamide gel.
Proteins were transferred to PVDV membrane and probed
with anti-p-tau (Ser396; 1:800 v/v; Abcam, England)
antibodies. After incubation with horseradish peroxidase–
conjugated secondary antibody (1:10000; BioRad, Hercules,
USA), immunoblots were developed using “Pierce ECL
Western Blotting Substrate” (Thermo Scientific, USA).
Membranes were stripped off and reprobed with anti-
β-tubulin antibody (1:2000 v/v; Cell Signaling, USA) for
loading control. Immunoblots were quantified by densi-
tometry (ImageJ, http://rsbweb.nih.gov/ij/). Data were nor-
malized to β-tubulin and the corresponding control was
taken as 100%.
Figure 2 Prevention of Aβ25–35- induced cytotoxicity by noopept. (A) The cells were pre-treated with noopept (10 μM) for 72 h before exposure
to 5 μM of Аβ25–35 for 24 h. Cell viability was determined by MTT assay. Data are expressed as means ± SEM. Five independent experiments were carried
out in triplicate. (B) Apoptosis was assessed by double staining of cells with Annexin-V-FITC and propidium iodide. The bar chart represents the percentage
distribution of apoptotic cells. Data are expressed as means ± SEM. Three independent experiments were carried out in triplicate.
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dPC12 cells (1 × 104 cells/well) were plated onto poly-
L-lysine coated coverslips in 24-well plates. After the
treatment, cells were fixed with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100 for 10 min and
stained with mouse monoclonal antibody to neuronspecific beta III tubulin (1:100; Abcam, England), followed
by AlexaFluor 488-conjugated secondary antibody
(1:1000; Invitrogen, USA). Coverslips were then incubated
with Hoechst 33258 (1 μg/ml) for 5 min at room
temperature. After washing out with PBS, samples were
mounted in Mowiol 4–88 based media (Sigma, USA).
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Zeiss, Germany) microscope with acquisition settings at
the maximal resolution (1024 × 1024 pixels) with 20x
objective. Morphological analysis of cells (the number of
neurites per cell and average neurite length) was carried
out with Sholl analysis (Sholl analysis plug-in for ImageJ,
http://rsbweb.nih.gov/ij/). Cells with at least one visible
process equal to or greater than one cell body were con-
sidered as positive for neurite formation. All neurites of
individual PC12 cell were traced, and the number of pixels
was automatically converted to micrometers. Comparison
of the number of processes between the experimental
groups was carried out at a distance of 55 μm from the
body of the cell. 50 randomly chosen cells were photo-
graphed and examined in each of three coverslips for each
experimental condition. Results were obtained from three
independent experiments.
Statistical analysis
Each of the above listed parameters was measured in 3 to
5 independent experiments with 3–5 technical replicates
per separate experiments. Statistical analysis was per-
formed by one-way analysis of variance (ANOVA) followed
by Turkey’s post-hoc test (Statistica v.6.0., StatSoft Inc.,
OK, USA). Data represent the mean ± SEM. A difference
was considered statistically significant if the p < 0.05.
Results
Effect of noopept on cell viability and apoptosis in
Aβ25–35-treated PC12 cells
A 24-h incubation of PC12 cells with Aβ25–35 (5 μM) de-
creased cell viability measured by MTT-test up to 32 ±
17.35%. Exposure of PC12 cells to noopept (10 μM, 72 h)
significantly (p = 0.025) reduced cell death caused by
Aβ25–35, increasing the cell viability to 230 ± 60.45%
(Figure 2A). Therefore exposure of PC12 cells to noopeptFigure 3 Effect of noopept on Аβ25–35-evoked disturbances of intracel
(A) Pre-treatment with noopept reduces the rate of intracellular calcium in PC1
enhancement of reactive oxygen species generation. (C) Noopept exposure am
Аβ25–35-caused stress. Results represent means ± SEM. The values were obtained
(A) and from five independent experiments with four technical replicates (B and(10 μM, 72 h) not only attenuated the cytotoxic effect of
Aβ25–35, but significantly (by about twofold comparing to
intact control) increased the cell viability.
Apoptosis was quantified by double staining of cells with
Annexin-V/PI (Figure 2B) to distinguish healthy PC12 cells
(Annexin V-negative, PI-negative) from early apoptotic
cells (Annexin V-positive, PI-negative) and late apoptotic
cells (Annexin V-positive, PI-positive). Annexin V/PI stain-
ing revealed an increase in the percentage of early and late
apoptotic cells from 5.1 ± 0.4 and 1.1 ± 0.4 in the control
group to 13.1 ± 1.2 and 8.3 ± 0.5 respectively following in-
cubation with Aβ25–35. Pretreatment of PC12 cells with
noopept (10 μM for 72 h) prior to Aβ25–35 exposure,
significantly decreased the percentage of Annexin V +/PI –
(up to 6.9 ± 1.3; p = 0.0023) and Annexin V +/PI + cells (up
to 4.9 ± 0.9; p = 0.0027), thus demonstrating the norma-
lizing drug effect on early as well as on late apoptotic
events.
Effect of noopept on Ca2+ level, ROS production and
mitochondrial membrane potential
It is well known that Aβ25–35-caused cell death is ac-
companied by the rise of Ca2+, ROS accumulation and
mitochondrial membrane potential disturbance in different
neuronal and neuron-like cells. Exposure of differentiated
PC12 cells to Aβ25–35 resulted in a 25% elevation of [Ca
2+]I,
while noopept statistically significantly (p = 0.027) inhi-
bited calcium rise (Figure 3A). By using of the ROS
fluorescent dye H2DCF-DA we were able to show that
Aβ25–35 caused a moderate increase in ROS level, which
was abolished by noopept (p = 0.0024) (Figure 3B). The
noopept ability to counteract the Aβ25–35-induced cyto-
toxicity was also assessed by monitoring of the changes in
the mitochondrial membrane potential using fluorescent
dye JC-1. When PC12 cells were incubated with Aβ25–35
(5 μM for 24 h) a reduction of MMP was detected.lular calcium level, ROS accumulation and mitochondrial function.
2 cells exposed to Aβ. (B) Noopept diminishes Аβ25–35 - induced
eliorates the mitochondrial membrane potential of PC12 cells after
from three independent experiments with five technical replicates
C).
Figure 4 Noopept decreases the tau phosphorylation induced
by Аβ in PC12 cells. Western blot analysis and graphs showed the
changes in the content of the phosphorylated tau (Ser396) in PC12
cells pre-treated with noopept following by Аβ25–35 incubation.
Densitometry values were normalized using the β-tubulin as internal
control and expressed as means ± SEM. Four independent experiments
were carried out using three replicate wells.
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brane potential against Aβ25–35 – induced mitochondrial
disturbance (p = 0.0023) (Figure 3C). Taken together data
obtained suggest that neuroprotective effect of noopept
against beta amyloid neurotoxicity involves the limiting of
oxidative stress, calcium disregulation and mitochondrial
dysfunction.Figure 5 Noopept protects the Аβ25–35- induced impairments of cells
neurites and (B) the average neurites length of PC12 cells after noopept pre-t
Data from three coverslips (50 cells per coverslip) for each experimental groupNoopept decreased tau phosphorylation induced by
Aβ25–35
The effect of Aβ25–35 on tau protein phosphorylation level
was measured by evaluating of the changes in immu-
noreactivity using anti-phospho-Ser396-tau antibodies. An
increased level of tau phosphorylation at Ser396 was
observed in the presence of 5 μM Aβ25–35, while the
pretreatment with noopept caused the decline of p-tau
Ser396 level (p = 0.0024) (Figure 4). Thus, the protective
effect of noopept on Aβ25–35 toxicity apparently involves
the attenuation of tau protein phosphorylation.
Noopept ameliorates Aβ-induced impairment of PC12
cells morphology
To further characterize the neuroprotective features of
noopept we investigated the effect of the drug on mor-
phology of differentiated PC12 cells. Quantification of
neuritic complexity by determination of the average
number and length of β-III-tubulin-immunopositive pro-
cesses and neurites number at different distances from
soma showed that PC12 cell treated with Aβ25–35 exhi-
bited unfavorable changes in their cytoarchitecture.
These changes were manifested in decreased number of
neurites per cell (2.3 in control cultures versus 1.6 in
Aβ-exposed cells), significantly reduced neurite length
(from 302 μM up to 129 μM) (Figure 5A, B) and a de-
crease of neurites number with increasing distance from
soma resulted in simplification of cells. The pretreatment
of cells with noopept tended to overcome these detrimen-
tal effects of Aβ. In particular, the drug restored the num-
ber of neurites (2.44 versus 1.64; p = 0.0022) and increased
their length compared to those in Aβ-treated group (frommorphology. (A) Quantification of number of IIIβ-tubulin - immunopositive
reatment following by Аβ25–35 addition. Data expressed as means ± SEM.
in three independent experiments were evaluated.
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the amount of longer neurites increased in noopept
treated cells, compared to cells exposed to Aβ25–35 alone.
Discussion
Present study revealed, for the first time, that the dipep-
tide cognition enhancing drug noopept protects differenti-
ated PC12 cells against Aβ-mediated toxicity as evidenced
by enhanced cell viability. While Aβ25–35 (5 μM) de-
creased cell viability, exposure of PC12 cells to noopept
has not only overcome the depressing effect of amyloid on
cells survival, but even increased it by about twofold com-
pared to intact control. Our results further indicate that
pre-treatment of the cells with noopept reduced the
percentage of apoptotic cells observed following incuba-
tion with the Aβ25–35 peptide. Using Annexin V-FITC/PI
double staining for the distinction of early- and late-
apoptotic cells, we demonstrated that noopept attenu-
ates both early and late apoptotic events induced by Aβ.
Our findings of antiapoptotic effect of noopept against
Aβ induced apoptosis are consistent with those ob-
tained with this dipeptide in SH-SY5Y cells under-
went to the toxic effect of another misfolded protein,
α-synuclein amyloids [24].
Numerous in vivo and in vitro studies indicate that
beta-amyloid triggers both common to different brain
damages pathogenic pathways by inducing the rise of
intracellular calcium level, reactive oxygen species produc-
tion, alteration of mitochondrial function, and Aβ-specific
signaling pathways resulted in increased tau phospho-
rylation [25]. Moreover, biochemical disturbances caused
by Aβ are accompanied by substantial cytoskeleton ab-
normalities and consequently impaired axonal transport
[26]. Particularly, prominent reductions of neurite out-
growth and neuritic elongation have been observed in
different neuronal and neuron-like cells after oligomeric
as well as fibrillar Aβ treatment [27,28].
In this study, noopept was found to mitigate the intra-
cellular calcium influx and excessive production of ROS,
suggesting that the neuroprotective effects of the drug in
this cellular model are probably associated with inhib-
ition of Aβ-induced overload of calcium and antioxidant
properties. Another mechanism involved in the neuro-
protective action of noopept likely includes its ability to
ameliorate mitochondrial dysfunction following Aβ25–35
exposure thereby interfering with mitochondrial apop-
totic pathway.
These data are in accordance with our previous find-
ings reporting neuroprotective action of noopept in vari-
ous in vivo and in vitro studies. Noopept was shown to
be able to normalize main secondary events by blocking
the voltage dependent calcium channels [29], attenuating
the neurotoxic effects of glutamate on granular cere-
bellar neurons [30], decreasing the glutamate release bycortical neurons [31]. Noopept significantly increased
neuronal survival and prevented the accumulation of
intracellular free radicals and apoptosis in experiments
on cultured Down’s syndrome neurons [16]. The drug
counteracted also the free radicals accumulation caused
by α-synuclein on cultured neuroblastoma SH-SY5Y
cells [24]. Interestingly, noopept was demonstrated to
increase immunoreactivity to β-amyloid in mice with
olfactory bulbectomy, considered as one of AD animal
models [18].
Here we have shown for the first time that noopept
can protect cells against Aβ-mediated toxicity by atte-
nuating an increased tau phosphorylation at Ser396.
Moreover, while Aβ-treated cells demonstrated decrease
of neurites number and their length, noopept was shown
to restore the number of neurites and significantly aug-
ment their processes length. It is known that extensively
phosphorylated tau protein forms pathologic inclusions
containing fibrillar aggregates were found in the brain of
patients suffering from certain neurodegenerative disor-
ders associated with dementias [32]. Tau protein is con-
sidered as one of the microtubules stabilizing proteins
playing important role in facilitation of tubulin assembly
into microtubules, thus contributing to the neurite out-
growth and maintenance of normal cellular morphology
[33,34]. Multiple studies provide evidence that the phos-
phorylation of tau at distinct serine/threonine residues
by different protein kinases affects the ability of tau to
promote microtubule polymerisation and stability [35].
Abnormally hyperphosphorylated tau possesses lower
affinity for microtubules; it promotes the cytoskeleton
rearrangements with consequent impairments of axonal
transport and intracellular trafficking [36]. Neurite out-
growth of neuronal cells requires the assembly of tubulin
into microtubules. The stability of microtubule network
depends, at least in part, on the rate and extent of tau
phosphorylation. Particularly, neurite outgrowth of neur-
onal and neuron-like cells was shown to correlate with the
phosphorylation of tau at Ser262, Ser356, Ser396/404;
these modifications reduce the ability of tau to bind to mi-
crotubules [37,35]. A number of studies suggest that Aβ
peptides under in vitro conditions can cause the increased
phosphorylation of tau protein at different sites, thus
provoking microtubules destabilization and cytoskeleton
network degeneration [38,26,39–41]. Indeed, exposure of
neuronal or neuron-like cells to the β-amyloid results in
pronounced neurite retraction and reduced cell com-
plexity [42–45] concomitant with a significant increase in
tau phosphorylation at the Ser 396 whereas other serine/
threonine sites – Ser199, Ser202, Thr205 and Ser404 show
no significant alteration [46,47]. Results from the present
study suggest that abrogation of tau hyperphosphorylation
at Ser396 by noopept eventually may play a role in restor-
ation and even improvement of PC12 cell morphology.
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this cellular model, probably depends on drug’s ability to
decrease the level of tau phosphorylation, thus affecting
tau binding to microtubules. It should be mentioned that
our previous experiments demonstrated noopept’ ability
to increase the expression of NGF and BDNF in hippo-
campal and hypothalamic neurons in streptozotocin -
intracerebroventricularly treated rats known to be an
experimental model of sporadic AD [20]. PC12 cells ex-
press TrkA and respond to NGF by neurite outgrowth
[48]. Findings of present study of noopept ability to exert
antiapoptotic effect and to increase number and length of
neuritis are in line with our supposition on the NGF
involvement in above described effects of noopept on
PC12 cells.
Recent studies provided evidence that both types of me-
dicines currently used for AD treatment, NMDA receptor
antagonists and AchE inhibitors, affect positively at least
some of AD-related mechanisms. For example memantine
was shown to inhibit the abnormal hyperphosphorylation
of tau [49] and protected the neurons from Aβ-induced re-
duction of neurite outgrowth [50]. AchE inhibitor galanta-
mine decreases the neuronal apoptosis induced by Aβ25–35,
as well as membrane potential dissipation, suppressing the
activity of caspase-9, caspase-12 and caspase-3 [51]. Results
comparable to those obtained for noopept were observed
for its conformationally related analog, piracetam. This cog-
nitive enhancer attenuates the Aβ-caused alterations of
mitochondrial membrane potential of PC12 cells and inhi-
bited the negative effect of Aβ on neurite outgrowth [52].
Taken together findings obtained in this study suggest
that noopept affects positively the core pathogenic
mechanisms underlying the Aβ-mediated toxicity and pro-
vide new insights into the neuroprotective action of this
drug and its possible beneficial effect in amyloid-related
pathology. Further studies to confirm the neuroprotective
effect of noopept against Aβ-induced neurotoxicity in AD
animal model need to be conducted.
Conclusions
Cognitive enhancer noopept exerts a protective effect
against Aβ25–35-induced toxicity in PC12 cells. The pro-
tective ability of noopept most likely results from mode-
rate suppression of oxidative stress and intracellular
calcium influx, stabilization of mitochondrial function and
reducing of apoptosis. Another possible mechanism by
which this compound protects cells from amyloid toxicity
may be related to the decrease of tau phosphorylation
and, eventually, neurite stabilization and outgrowth.
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